Loading clinical trials...
Loading clinical trials...
This study will assess the safety, tolerability, and pharmacokinetics of DS-6016a after subcutaneous injection in healthy Japanese participants.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Daiichi Sankyo Co., Ltd.
NCT04307953 · Fibrodysplasia Ossificans Progressiva
NCT05394116 · Fibrodysplasia Ossificans Progressiva
NCT06508021 · Fibrodysplasia Ossificans Progressiva
NCT06064656 · Fibrodysplasia Ossificans Progressiva (FOP)
NCT05027802 · Fibrodysplasia Ossificans Progressiva (FOP)
Medical Corporation Heishinkai OPHAC Hospital
Osaka
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions